NCT07080567RecruitingPhase 2
Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke
Maraviroc for Stroke Recovery (MASTER): A Phase 2 Double-Blind Placebo-Controlled Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 12 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 2 Jul 2025
- Start date
- Jul 2025
- Primary completion date
- Dec 2027
- Lead sponsor
- Emmanuel Carrera
- Diseases
- Stroke
- NCT number
- NCT07080567
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 80
- From Jul 2025 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant use of strong CYP3A4 inhibitors or inducers
Other illness
- Pre-stroke handicap (mRS \> 2)
- Diseases affecting motor function (e.g., Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS))
- Known hypersensitivity to Maraviroc, Mannitol, peanuts, or soy
- History of significant liver disease, hepatitis, elevated liver function tests (\> 1.5 upper limit of normal)
- HIV infection
Lab values
- History of significant renal disease or End Stage Renal Disease/dialysis, acute renal injury, Creatinine Clearance (CrCl \< 30ml/min/1.73m2)
Age
- Pregnancy/lactation or positive pregnancy test in women of childbearing age
Other
- Participation in another study with investigational medicinal product within 30 days preceding and during the present study
- Enrolment of the investigator, his/her family members, employees, or other dependent persons
- Patients with cardiovascular comorbidities and risk for orthostatic hypotension
Who the study is looking for
- Informed consent as documented by signature
- ≥18 years at time of signing of informed consent
- Acute ischemic stroke.
- Stroke onset \< 7 days from randomization.
- Contralateral, unilateral, incomplete upper limb paresis, incl. :
- FMA-UE \< 63/66
- Residual voluntary finger extension (VFE) of \> 10 degrees
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Geneva University Hospital Coordinator of this site? Confirm its status | Geneva | Switzerland | Recruiting |
Related publications
- Maraviroc for Stroke Recovery (MASTER): protocol for a phase 2 double-blind placebo-controlled randomised clinical trial.BMJ Open · 2026 · PMID 42082248
This page is information, not medical advice. Discuss any trial with your doctor.